CASI Pharmaceuticals (CASIF) Cash & Current Investments (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Cash & Current Investments data on file, last reported at $5.6 million in Q4 2025.

• Quarterly Cash & Current Investments fell 58.42% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (down 58.42% YoY) and the FY2025 annual result came in at $5.6 million, down 58.42% from the prior year.
• Cash & Current Investments advanced to $5.6 million in Q4 2025, from $4.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $19.9 billion in Q2 2023 to a low of $9533.0 in Q2 2024.
• A 5-year average of $1.7 billion and a median of $12.8 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments sank 100.0% — and 2025, when it jumped 70601.77%.
• Tracing CASIF's Cash & Current Investments over 5 years: stood at $48.6 million in 2021, then advanced by 0.0% to $48.6 million in 2022, then slumped by 40.1% to $29.1 million in 2023, then tumbled by 53.71% to $13.5 million in 2024, then slumped by 58.42% to $5.6 million in 2025.
• The last three Cash & Current Investments figures came in at $5.6 million (Q4 2025), $4.7 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.